Lia DeGroot

Pfiz­er has restart­ed most of its man­u­fac­tur­ing lines that were im­pact­ed by tor­na­do dam­age ear­li­er this sum­mer at its fa­cil­i­ty in Rocky Mount, North Car­oli­na,

The CDC’s vac­cine ad­vi­sors on Fri­day af­ter­noon vot­ed 11-1 to rec­om­mend Pfiz­er’s ma­ter­nal RSV vac­cine for preg­nant peo­ple at 32 to 36 weeks of ges­ta­tion

Boehringer In­gel­heim and Eli Lil­ly nabbed a sec­ond FDA ap­proval for block­buster Jar­diance (em­pagliflozin), this time to treat adults with chron­ic kid­ney dis­ease, the com­pa­nies

I2o Ther­a­peu­tics CEO Kurt Graves set out on Thurs­day to make a case to a pan­el of the FDA’s ex­pert ad­vi­sors that the ben­e­fits of

Af­ter be­ing re­ject­ed twice by the FDA in the past six years, Intar­cia Ther­a­peu­tics’ drug-de­vice prod­uct to treat type 2 di­a­betes will be the sub­ject

House law­mak­ers pressed the CMS on a re­cent re­port show­ing that Medicare ben­e­fi­cia­ries pay more for pre­scrip­tion drugs than their plan spon­sors as they dou­bled

As pol­i­cy­mak­ers con­tin­ue to chip away at fix­es to on­go­ing drug short­ages, the FDA’s drug cen­ter head is urg­ing man­u­fac­tur­ers to work with FDA on

House law­mak­ers have re­turned from re­cess with their work cut out for them to ad­dress on­go­ing drug short­ages, but reach­ing bi­par­ti­san con­sen­sus on how to

FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search is ob­ject­ing to On­copep­tides’ ap­peal of the agency’s re­quest to with­draw its can­cer drug Pepax­to. Pepax­to was first

The CDC’s vac­cine ad­vi­so­ry pan­el vot­ed 13-1 to rec­om­mend an up­dat­ed Covid-19 boost­er for peo­ple ages 6 months and old­er, a day af­ter the FDA